NCT06106152View on ClinicalTrials.gov

WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

December 31, 2025

Conditions
Advanced Lung Cancer
Interventions
DRUG

WTX212A injection

The WTX212A infusion is given every 21 days

DRUG

PD -1/PD-L1 monoclonal antibody

The PD -1/PD-L1 monoclonal antibody is given every 21 days

Trial Locations (1)

310000

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Westlake Therapeutics

INDUSTRY

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER